Search results
Hugh Auchincloss, Jr. (pronounced: aa-kuhn-klaas; born March 15, 1949) is an American immunologist and physician serving as the acting director of the National Institute of Allergy and Infectious Diseases since 2023. He previously served as the principal deputy director between 2006 and 2022.
Mar 29, 2023 · This is an oral history with Dr. Hugh Auchincloss, Jr., on November 28, 2022, about his career at the National Institute of Allergy and Infectious Diseases (NIAID).
Feb 11, 2023 · Auchincloss, 73, a respected transplant surgeon and medical researcher, served for more than 16 years as Fauci’s low-key right-hand man at NIAID, a post he took after a long career at...
Auchincloss is associate professor of surgery at Harvard Medical School and associate visiting surgeon at Massachusetts General Hospital, as well as chair of the FDA's Subcommittee on Xeno ...
Hugh Auchincloss, Jr., M.D., has been named Principal Deputy Director of NIAID. In that capacity, he will serve as second in command to NIAID Director Anthony S. Fauci, M.D., and will have broad responsibilities for carrying out the Institute’s many programs.
Sep 15, 2023 · With each new universal influenza vaccine candidate and clinical trial, we take another step closer to that goal,” said Acting NIAID Director Hugh Auchincloss, M.D. The vaccine candidate under investigation, FluMos-v2, was designed by researchers at NIAID’s Vaccine Research Center (VRC).
Sep 22, 2023 · “The evidence is clear that immune modulation can be beneficial for severely ill COVID-19 patients,” said NIAID Acting Director Hugh Auchincloss, M.D. “Patients with milder cases of COVID-19 are often administered one immune modulator, and a second treatment is added only if the patient becomes severely ill.
